Mylan gets DGCI nod, to launch generic remdesivir at Rs 4,800 per vial

Drugmaker Mylan NV said on Monday it would launch its generic version of Gilead Sciences Inc's Covid-19 treatment remdesivir in India this month at Rs 4,800 ($64.31) per 100 mg vial, as infections surge in the world's third worst-hit country.

The Drug Controller General of India (DCGI) approved Mylan's remdesivir version, to be called Desrem, for the treatment of suspected or laboratory-confirmed severe incidences of Covid-19 in adults and children, the company said in a statement.

Mylan's version comes after two Indian drugmakers, Cipla Ltd and privately-held Hetero Labs Ltd, launched their generic versions of the drug.

Cipla will price